CTMX — CytomX Therapeutics, Inc. stock price, charts and financials

QT38CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.32
+0.15+4.73%
OverviewShort InterestFilings
CTMXQT38CytomX Therapeutics, Inc.·NASDAQ
3.32+4.73%

Latest SEC Filings

Form category
Filing Date ▾FormDescriptionFilingDocument
Aug 03, 2026SC 13GBeneficial ownership statement (passive)
Jul 30, 20263Initial statement of beneficial ownership
Jul 30, 20264Statement of changes in beneficial ownership
Jul 27, 20268-KCurrent report
Jul 27, 2026SC 13GBeneficial ownership statement (passive)
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20264Statement of changes in beneficial ownership
Jun 22, 20268-KCurrent report
Jun 17, 20264Statement of changes in beneficial ownership
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 07, 20268-KCurrent report
May 07, 202610-QQuarterly report
Apr 30, 2026DEFA14AAdditional proxy soliciting materials
Apr 30, 2026DEF 14ADefinitive proxy statement
Apr 20, 2026PRE 14APreliminary proxy statement
Apr 16, 2026SC 13GBeneficial ownership statement (passive)
#1 / 25 of 309
Page
▼
/ 13